Werewolf Therapeutics, Inc. (HOWL) has disclosed a new risk, in the Capital Markets category.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Werewolf Therapeutics, Inc. could face significant business risks due to changes in U.S. and international trade policies, particularly those concerning China. Recent U.S. government actions, such as tariffs and export controls, alongside potential legislation like the BIOSECURE Act, may disrupt supply chains and increase operational costs. These measures could hinder the company’s ability to source materials and collaborate with Chinese biotechnology firms, thereby affecting product development and business operations. The uncertainty surrounding future trade policies and potential retaliatory actions underscores the geopolitical vulnerabilities impacting their financial stability and operational efficiency.
The average HOWL stock price target is $7.00, implying 455.56% upside potential.
To learn more about Werewolf Therapeutics, Inc.’s risk factors, click here.